Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial.

Zhang J, Xian TZ, Wu MX, Li C, Wang W, Man F, Zhang X, Wang X, Pan Q, Guo L

Journal of investigative medicine : the official publication of the American Federation for Clinical Research20 Jun 2022Cited by 3 (Europe PMC)

PMID35725020DOI10.1136/jim-2021-002237PepBankPUB-35725020

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, eGFR differed between exenatide and insulin at 52 weeks, without a stated direction.
In plain wordsKidney filtration differed between exenatide and insulin after treatment, but the abstract did not state the direction.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedeGFR between treatments
Study
n: not reported in source
Comparator
Insulin
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
There was a significant difference in eGFR between the insulin and exenatide groups at 52 weeks (p=0.0135).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM.
Report a problemFND-3572502001
02HumanRandomized controlled trialEfficacy outcome
In normal-weight patients with T2DM, eGFR rose significantly above baseline during exenatide treatment.
In plain wordsKidney filtration increased from baseline during exenatide treatment in normal-weight patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseeGFR in normal weight
Study
n: not reported in source
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
A decrease in body weight was prominent in the exenatide group at 52 weeks (p<0.05), the eGFR was below baseline in overweight patients and patients with obesity and significantly above baseline in the normal group (p<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM.
Report a problemFND-3572502004
03HumanRandomized controlled trialEfficacy outcome
In patients with T2DM, body weight decreased during exenatide treatment.
In plain wordsBody weight decreased during exenatide treatment in patients with diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
A decrease in body weight was prominent in the exenatide group at 52 weeks (p<0.05),
1 context sentence(design, population, supporting numbers)
Summary · context
Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM.
Report a problemFND-3572502002
04HumanObservational studyMechanism
In exenatide-treated patients with T2DM, eGFR did not correlate positively with 8-oxo-7,8-dihydroguanosine.
In plain wordsKidney filtration did not show a positive link with the oxidative stress marker in patients receiving exenatide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeeGFR association with oxidative stress
Study
n: not reported in source
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Source sentences
Summary
The eGFR was positively correlated to 8-oxo-7,8-dihydroguanosine in the insulin group (p<0.05) but not the exenatide group.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM.
Report a problemFND-3572502005

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In overweight patients and patients with obesity and T2DM, eGFR remained below baseline in both treatment groups.
In plain wordsKidney filtration remained below baseline in both treatment groups among patients with diabetes and overweight or obesity.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseeGFR in overweight and obesity
Study
n: not reported in source
Analysis
Primary
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
A decrease in body weight was prominent in the exenatide group at 52 weeks (p<0.05), the eGFR was below baseline in overweight patients and patients with obesity and significantly above baseline in the normal group (p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Within the insulin group, the eGFR remained below baseline at 52 weeks in all patients, and there was an increase in body weight in the normal group compared with the overweight patients and patients with obesity.
Summary · context
Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3572502003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.